4.510USDMkt Cap: 98.39M USDP/E: —Last update: 2026-05-21
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therape…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap98.39M USD
Enterprise Value7.53M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-57.59M USD
Revenue/Share—
Last Price4.510 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees40
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.39
PEG—
EV/EBITDA-0.10
EV/Revenue—
P/S—
P/B1.13
EPS (TTM)-3.21
EPS (Forward)-3.24
52W Range
4.05074% of range4.670
52W High4.670 USD
52W Low4.050 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-54.01%
ROA-49.15%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-54.17M USD
CapEx (TTM)95.00K USD
FCF Margin—
FCF Yield-35.00%
Net Debt-90.86M USD
Net Debt/EBITDA1.22
Balance Sheet
Debt/Equity0.00
Current Ratio8.06
Quick Ratio7.86
Book Value/Sh3.987 USD
Cash/Share4.180 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Target (Mean)15.44 USD
Target Range3.000 USD – 45.00 USD
# Analysts9
Ownership
Shares Out.21.82M
Float10.91M
Insiders16.15%
Institutions56.43%
Short Interest
Short Ratio7.0d
Short % Float8.76%
Short % Out.5.78%
Shares Short1.26M
Short (prev mo.)1.13M
Technical
SMA 504.849 (-7.0%)
SMA 20010.07 (-55.2%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)164.53K
Avg Vol (10d)226.68K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—